WS Value & Dossier GmbH
Your specialists for market access and reimbursement
How the German AMNOG process works
Value & Dossier GmbH advises pharmaceutical companies and biotechnology companies throughout the AMNOG process and on all matters relating to market access and reimbursement. Based on our long-standing expertise, we advise you on the development of the best strategy, the preparation of your benefit dossier for the G-BA assessment and the price negotiations with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband).
Your success is what drives us. We will make sure that your new product will be reimbursed in the best possible way.
Our Services
Strategic Market Access Consulting
German Benefit Assessment (AMNOG)
AMNOG price negotiations 
Reference pricing for pharmaceuticals
European Health Technology Assessment (EU-HTA)
European Reference Price Calculator
Reimbursement of Medical Devices
HTA Services“We offer individual and company-specific solutions focussing on the value of the product while implementing it accordingly in the required benefit dossiers.”
Your team of specialists from Value & Dossier
f. l. t. r.: Dr. Hanna Klimek, Dr. Angela Lammert, Christopher Bell M. Sc., Julia Gerbeth M. Sc., Dr. Willi Schnorpfeil, Dr. Sandra Kiehlmeier, Michelle Woods M. Sc., Sandra Fraatz
Recent Articles
European Reference Pricing is discontinued in Germany
Figure 1: Number of reference prices used by each country Changes to the German pricing
Confidential reimbursement amount – Only for pharmaceutical companies with R&D in Germany
Figure 1: Requirements, pros and cons for the confidential reimbursement amount in Germany Confidential reimbursement
Our new AMNOG Negotiation Guide is online now!
With the SHI Financial Stabilisation Act (GKV-FinStG), the framework conditions for price negotiations for medicinal products in